此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Effects of Omega-3 Fatty Acids on Inflammation and Gut Microbiota in Celiac Disease (OMEGA-CD)

2026年5月6日 更新者:University of Chile

Modulation of Blood and Small Intestinal Inflammatory Processes and Fecal Microbiota in Celiac Disease Associated With the Intake of n-3 Polyunsaturated Fatty Acids

The goal of this clinical trial is to learn if omega-3 fatty acid supplements (n-3 PUFAs) can help reduce inflammation and promote intestinal healing in adults newly diagnosed with celiac disease (CD).

Celiac disease is a chronic autoimmune disorder where eating gluten-a protein found in wheat-triggers an immune response that damages the lining of the small intestine. This damage causes inflammation and symptoms such as stomach pain, diarrhea, and nutrient absorption problems. The only current treatment is a strict gluten-free diet (GFD), which can help most people recover, but some continue to have inflammation and symptoms.

This study will test whether supplementing with 2.4 grams of n-3 PUFAs daily for three months, alongside starting a gluten-free diet, reduces inflammation in the blood and intestine more effectively than the gluten-free diet alone.

Participants will:

Be adults recently diagnosed with celiac disease who have not yet started a gluten-free diet

Be randomly assigned to one of two groups:

One group will receive omega-3 supplements containing 2,400 mg of n-3 PUFAs daily (2,000 mg DHA and 400 mg EPA) The other group will receive a placebo (a pill with no active ingredients that looks like the supplement) Take the assigned supplement every day for 3 months while following a supervised gluten-free diet Visit the clinic regularly for checkups, blood tests, and monitoring of symptoms and diet adherence Provide blood and stool samples before and after the intervention to measure inflammation and changes in gut bacteria A subgroup of participants will undergo small intestinal biopsies to assess local inflammation and healing

The study aims to answer these main questions:

Does omega-3 supplementation change the fatty acid composition in blood cells? Does it reduce markers of inflammation in the blood and small intestine? Does it improve the diversity and health of gut bacteria in the intestine? Does it help the small intestine heal faster compared to diet alone?

Researchers will measure inflammation by analyzing immune signaling pathways, oxidative stress markers, and antioxidant activity in blood cells. They will also study the composition of the gut microbiota and its metabolites. These detailed measurements will help understand how omega-3 fatty acids may influence the immune response and gut health in celiac disease.

This is a randomized, double-blind, placebo-controlled crossover study. This means participants and researchers will not know who receives the supplement or placebo during the study period, reducing bias and improving the reliability of the results.

This study is important because it could offer a simple, additional treatment to improve recovery in celiac disease beyond the gluten-free diet. If omega-3 supplements are shown to reduce inflammation and support healing, they could become a valuable part of managing this chronic condition.

Participation is voluntary, and participants can leave the study at any time without affecting their medical care. All participants will be closely monitored to ensure safety throughout the study.

研究概览

研究类型

介入性

注册 (估计的)

40

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • Metropolitan Region
      • Santiago、Metropolitan Region、智利、8380000
        • 招聘中
        • University of Chile Clinical Hospital
        • 接触:
          • Paulina Toledo (Clinical Research Coordinator)+569
          • 电话号码:987299944
          • 邮箱:ptoledo@hcuchi.cl

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

不

描述

Inclusion Criteria:

  • Adult patients aged 18 to 65 years, Newly diagnosed with celiac disease confirmed by serology and intestinal biopsy, Not yet started gluten-free diet (GFD), Willingness to adhere to a supervised gluten-free diet during the study, Able to provide informed consent

Exclusion Criteria:

  • Previous or current adherence to a gluten-free diet, Use of n-3 PUFA supplements or other dietary supplements influencing inflammation within the last 3 months, Presence of other autoimmune, inflammatory, or gastrointestinal diseases (e.g., Crohn's disease, ulcerative colitis), Pregnancy or breastfeeding, Severe chronic illnesses that may interfere with the study or outcomes (e.g., uncontrolled diabetes, cancer), Allergy or intolerance to fish oil or components of the supplement, Use of immunosuppressive or anti-inflammatory medication within the last 3 months

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:交叉作业
  • 屏蔽:双倍的

武器和干预

参与者组/臂
干预/治疗
实验性的:Omega-3 PUFA Supplement
Participants in this group will receive daily oral supplementation with 2,400 mg of omega-3 polyunsaturated fatty acids (2,000 mg DHA and 400 mg EPA) for 3 months. All participants will start a supervised gluten-free diet at the same time. Clinical symptoms, dietary adherence, and safety will be monitored throughout the intervention period.
n-3 PUFAs supplementation consisting of 2,400 mg per day (2,000 mg docosahexaenoic acid [DHA] and 400 mg eicosapentaenoic acid [EPA]), administered orally for 3 months in newly diagnosed adult celiac disease patients. The supplementation is given alongside the initiation of a gluten-free diet (GFD). The aim is to assess whether supplementation modulates the inflammatory response and supports intestinal recovery. This is part of a randomized, double-blind, placebo-controlled, crossover trial comparing supplementation versus placebo.
其他名称:
  • Omega-3 脂肪酸
  • DHA + EPA
安慰剂比较:Placebo
Participants in this group will receive a daily oral placebo supplement, identical in appearance and taste to the omega-3 supplement, for 3 months. All participants will begin a supervised gluten-free diet at the same time. Clinical symptoms, dietary adherence, and safety will be monitored throughout the intervention period.
Placebo capsules identical in appearance and taste to the active n-3 polyunsaturated fatty acid (PUFA) supplement, administered orally once daily for 3 months in newly diagnosed adult celiac disease patients. Participants will simultaneously begin a supervised gluten-free diet. This intervention serves as a control to evaluate the effect of the active supplement on modulating the inflammatory response and intestinal recovery.
其他名称:
  • 安慰剂胶囊
  • 安慰剂补充剂

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Modulation of systemic inflammatory response via cytokine levels and NF-κB signaling in peripheral blood mononuclear cells
大体时间:From baseline (T0) to 3 months (T3) of supplementation
Levels of proinflammatory cytokines and NF-κB signaling in peripheral blood mononuclear cells will be measured to assess the reduction of systemic inflammation in newly diagnosed adult celiac patients receiving n-3 PUFA supplementation versus placebo.
From baseline (T0) to 3 months (T3) of supplementation

次要结果测量

结果测量
措施说明
大体时间
Changes in fatty acid composition of erythrocyte and peripheral blood mononuclear cell membranes
大体时间:From baseline (T0) to 3 months (T3) of supplementation
The fatty acid profiles of erythrocyte and peripheral blood mononuclear cell membranes will be analyzed at baseline and after 3 months to assess the impact of n-3 PUFA supplementation on membrane lipid composition in adult celiac disease patients.
From baseline (T0) to 3 months (T3) of supplementation

其他结果措施

结果测量
措施说明
大体时间
Evaluation of intestinal inflammation and microbiota composition in newly diagnosed celiac disease patients following n-3 PUFA supplementation
大体时间:From baseline (T0) to 3 months post-intervention (T3)

Assessment of local intestinal inflammation and gut microbiota changes in newly diagnosed adult celiac disease patients receiving 2.4 g/day of n-3 polyunsaturated fatty acids alongside a supervised gluten-free diet. Intestinal biopsies and fecal samples will be collected at baseline (T0) and after 3 months (T3) to measure inflammatory markers (e.g., NFκB, pro-inflammatory cytokines, I-FABP) and characterize fecal microbiota diversity and short-chain fatty acid profiles. This will determine the impact of n-3 PUFA supplementation on mucosal inflammation and the intestinal microenvironment.

Time Frame:

From baseline (T0) to 3 months post-intervention (T3)

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2025年10月1日

初级完成 (估计的)

2026年10月30日

研究完成 (估计的)

2026年12月30日

研究注册日期

首次提交

2026年5月6日

首先提交符合 QC 标准的

2026年5月6日

首次发布 (实际的)

2026年5月14日

研究记录更新

最后更新发布 (实际的)

2026年5月14日

上次提交的符合 QC 标准的更新

2026年5月6日

最后验证

2025年11月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

De-identified individual participant data (IPD) collected during this study will be made available to qualified researchers upon reasonable request after publication of the primary study results. Data sharing requests will be reviewed by the study steering committee to ensure appropriate use and compliance with ethical and privacy regulations. Data will be shared through a secure data repository, and a data use agreement will be required.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅